title: [The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology].
abstract: Procedures, connected with extracorporal blood circulation--hemodialysis, hemosorption and plasmapheresis--were used in complex of treatment in 30 patients with various cardiovascular diseases. As an anticoagulant in 8 patients was used the preparation of low molecular heparine (Fraxiparine) produced by "Sanofi" (France) firm, and in 22-heparin, produced by "Polfa" (Poland). Ascertained advantages of Fraxiparine versus heparin were: possibility of single injection of preparation, the reducing of total dose magnitude, which is needed for one curative act conduction, lowering by 70% approximately the hemorrhagic complications rate.
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Sirenko
authors.forename: O S
authors.initials: OS
authors.lastname: Sychev
authors.forename: M N
authors.initials: MN
authors.lastname: Reĭko
authors.forename: M B
authors.initials: MB
authors.lastname: Shchupak
authors.forename: P I
authors.initials: PI
authors.lastname: Sidorenko
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000628:therapy*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use*; D016060:Sorption Detoxification / Q000379:methods*
chemical_list: D000925:Anticoagulants; D017762:Nadroparin; D006493:Heparin